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ened the strand development to a similar
embryologic process in bicuspid aortic
valve cases. The causes of such a strand
formation may be more complicated than
those of previously reported cases associ-
ated with bicuspid aortic valves. Ours and
other cases had a strand between the fused
valve and the aortic wall, whereas their
case had three pairs of strands in three
leaflets. It is not easy to explain these for-
mations as embryogenic remnants. As Na-
kajima and associates1 mentioned, how-
ever, their case may indicate another aspect
for aortic valve surgery. Suspending a pro-
lapsed aortic valve between its leaflets and
the aortic sinotubular junction with a paired
artificial strands may be an option for aortic
valve repair. Additional case reports and
hemodynamic and physiologic confirma-
tion will be necessary.
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Do macrophages and monocytes
impede regeneration of transplanted
cardiomyocytes?
To the Editor:
I read with great interest the article of To-
mita and colleagues1 entitled “Improved
Heart Function With Myogenesis and An-
giogenesis After Autologous Porcine Bone
Marrow Stromal Cell Transplantation” in a
recent issue of the Journal. My research
team has had similar results in both our
animal and clinical experiences. In our an-
imal experience, however, a lack of fibrous
tissue in the infarcted region after cell
patch cardiomyoplasty and omentopexy
procedures prompts me to believe that
macrophages and monocytes may contrib-
ute importantly to the disappearance of fi-
brotic tissue, thus preventing the regenera-
tion of the myocytes from progressing. I
therefore wonder whether similar findings
were seen in Tomita and colleagues1 cell
transplant experiments. I would greatly ap-
preciate a response to this inquiry.
S. Taheri, MD
Suite C
9095 Main St
Clarence, NY 14031
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Problems in assessment of serum
carcinoembryonic antigen levels in
cancers
To the Editor:
In a recent issue, Saito and colleagues1
reported on a multicenter retrospective re-
view of surgery for pulmonary metastasis
from colorectal cancer. They concluded
that the status of the hilar or mediastinal
lymph nodes and prethoracotomy carcino-
embryonic antigen (CEA) level were sig-
nificant independent prognostic factors. I
believe these findings are useful in the fol-
low-up of patients who have undergone
resection of pulmonary metastasis of colo-
rectal cancer. Prethoracotomy serum CEA
levels are also a prognostic indicator in
non–small cell lung cancer when the cutoff
level is defined as 6. 9 ng/dL on the basis of
the 95% specificity level for benign lung
disease.2
There are many kits to measure serum
CEA levels. The antibodies used by the
various methods vary. Thus there are some
cross-reactive normal antigens that are cal-
culated by some kits, and the maximum
normal serum level of CEA ranges from
2.5 ng/dL to 6.9 ng/dL.3 In the study that
Saito and colleagues1 conducted, 10.0
ng/dL was used as a cutoff level that influ-
enced the prognosis. This level is from 1.4
times to 4 times the upper limit of normal
for serum CEA level.
In a multicenter study, the variable for
serum CEA level should be considered nor-
mal or high according to a cutoff level
established by each individual institution.
Otherwise, the specification of a single
type of kit to measure serum CEA levels is
needed when a specific serum CEA level is
defined as the cutoff level. Either method, I
believe, will make serum CEA levels a
more significant prognostic indicator for
patients with lung cancer or patients with
pulmonary metastases from colorectal can-
cer.
Noriyoshi Sawabata, MD
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Reply to the Editor:
My coauthors and I appreciate the com-
ments of Sawabata concerning our article.
As he states, during the long term of our
retrospective study, several methods, such
as enzyme immunoassay and radioimmu-
noassay, were used to measure serum car-
cinoembryonic antigen (CEA) levels.
Many kits to measure serum CEA levels
are available in Japan, and results vary with
each assay. This leads to confusion among
physicians when evaluating serum values
detected by the different assay kits. One
does need to pay attention when evaluating
such archival data stored in medical
records.
In a multi-institutional study, ideally all
data from various institutions would be
measured by the same method with identi-
cal assay kits. However, it may be difficult
to measure serum CEA with the same assay
kit in each institution for various reasons,
including cost considerations and available
assay equipment. Moreover, the kits com-
monly used in Japan may be different from
ones used in the United States or Europe,
also making it difficult to compare the data
among them. It may be necessary to set up
an international committee to solve the is-
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sue of CEA measurement standardization.
Until then, the comparison method pro-
posed by Sawabata and colleagues in their
own article1 is a good and satisfactory so-
lution for this problem.
Among the 108 patients in our study,
serum CEA levels were measured in 97
with enzyme-linked immunosorbent assay
kits that use 5.0 ng/mL as the upper limit of
normal. In the remaining 11 cases, CEA
levels were measured by a different
method. Their serum CEA levels were cal-
culated according to the following conver-
sion formula2: (Y  1.23  X  0.44).
The converted data were used in our study.
Multi-institutional studies in various
medical fields are on going between Japan
and other countries. We look forward to a
time when CEA values are standardized by
an efficient conversion formula that will
not confuse physicians and surgeons. We
thank Sawabata for his appropriate com-
ments.
Yukihito Saito, MD, PhD
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